Hamilton Thorne to accelerate acquisition program

Hamilton Thorne (TSX-V:HTL), a leading provider of precision laser devices and advanced imaging systems, plans to accelerate its acquisition program, mainly in the human clinical in-vitro fertilization (IVF) market, as part of a long-term growth strategy that also includes product innovation and organic growth.

“Our goal is to expand our product portfolio and capabilities with acquisitions of complementary products and businesses in order to provide a full range of instruments, consumables and services in IVF labs,” president and CEO, David Wolf, says in an interview with BioTuesdays.com.

“We are in active discussions on the acquisition front and have identified over 120 companies that fit into our strategy, of which 50-to-60 are in the Americas and northern and western Europe, and are realistic targets for 2016,” he adds.

READ THE FULL INTERVIEW HERE

Subscribe to Our Investor Email List